Posts for Ticker ‘MNTA’

Weekend of Cancer Data at AACR Ahead of ASCO (ALTH, AMGN, ARIA, ARRY, AZN, BIIB, CELG, CRIS, IMMU, IMGN, INFI, MEDX, MNTA, ONCY, PFE, PCYC, SUPG, TELK, THLD)

This weekend will be a potentially important oncology and cancer news weekend for drug and biotech stocks.  The American Association for Cancer Research Meeting will actually have a 100th annual meeting, and some traders and investors may be using this as a preview for what lies ahead at the American Society of Clinical Oncology (ASCO) annual meeting in a month.  The following companies which are presenting data:

  • Allos Therapeutics, Inc. (NASDAQ: ALTH)
  • Amgen (NASDAQ: AMGN)
  • ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA)
  • Array BioPharma, Inc. (NASDAQ: ARRY)
  • AstraZeneca’s (NYSE: AZN) Medimmune unit
  • Biogen Idec Inc. (NASDAQ: BIIB)
  • Celgene Corporation (NASDAQ: CELG)
  • Curis, Inc. (NASDAQ: CRIS)
  • Immunomedics, Inc. (Nasdaq: IMMU)
  • ImmunoGen, Inc. (Nasdaq: IMGN)
  • Infinity Pharmaceuticals, Inc. (NASDAQ: INFI)
  • Medarex, Inc. (Nasdaq: MEDX)
  • Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA)
  • Oncolytics Biotech, Inc. (NASDAQ: ONCY)
  • Pfizer (NYSE: PFE)
  • Pharmacyclics, Inc. (NASDAQ: PCYC)
  • SuperGen Inc. (NASDAQ:SUPG)
  • Telik, Inc. (Nasdaq: TELK)
  • Threshold Pharmaceuticals, Inc. (Nasdaq: THLD)

You can see a full summary of the data being presented at BioHealthInvestor.com site.  There will be others presenting data this weekend, and these were from the press releases of the meeting ahead of time.

JON C. OGG

Posted on: April 17, 2009 – 2:05 pm in Biotech, Calendar, Drug companies, , , , , , , , , , , , , , , , , , ,

Top 10 Pre-Market Analyst Calls (BIG, CSH, CS, ERIC, GT, MRVL, MMR, MNTA, NTRS, PCZ)

These are ten of the top analyst calls we see affecting shares in pre-market indications this Monday morning:

  • Big Lots (NYSE: BIG) Raised to Overweight from Neutral at JPMorgan.
  • Cash America (NYSE: CSH) Cut to Hold from Buy at Jefferies.
  • Credit Suisse (NYSE: CS) Raised to Peer Perform at Bear Stearns.
  • Ericsson (NASDAQ: ERIC) raised to Neutral from to Sell at Goldman Sachs; downgraded to Neutral from Buy at Banc of America.
  • Goodyear Tire & Rubber (NYSE: GT) cut to Neutral at JP Morgan.
  • Marvell Tech (NASDAQ: MRVL) raised to Outperform at FBR (stock indicated +2%).
  • McMoRan Exploration (NYSE: MMR) Cut to Hold from Buy at Jefferies.
  • Momenta Pharmaceuticals (NASDAQ: MNTA) Raised to Overweight at Morgan Stanley.
  • Northern Trust (NASDAQ: NTRS) Cut to Hold from Buy at Deutsche Bank.
  • Petro-Canada (NYSE: PCZ) raised to Outperform at CINC World Markets.

Jon C. Ogg
April 28, 2008

Posted on: April 28, 2008 – 6:33 am in Analyst Calls, , , , , , , , , ,

Biotech News Day (February 4, 2008) (AMAG, AOB, AMGN, CELG, MNTA, OMRI, SVA, STEM)

Below are some of the top issues affecting biotech shares today:

  • AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company developing iron compounds to treat anemia, saw shares rise 4% to $56.00 after brokerage firm Robert W. Baird initiated coverage with an OUTPERFORM rating.
  • American Oriental Bioengineering Inc. (NYSE:AOB) shares are down almost 7% at mid-day with relative high volume trading to $9.50 on no real news.
  • Amgen Inc. (NASDAQ:AMGN) stock shows no reaction to deal with Japanese drug giant Takeda Pharmaceutical. Takeda is to purchase Amgen’s Japanese unit for up to $902 million plus royalties on sales in exchange for access to 13 of Amgen’s new drugs. Amgen hopes this will curb costs and provide cash as their high-selling anemia drug sales slow due to safety issues. 
  • Celgene Corporation (NASDAQ:CELG) shares are down $1.76 to $57.94 at mid-day. Although earnings reported last Thursday met Wall Street expectations, the outlook for the success of its multiple myeloma cancer treatment, Revlimid, is mixed. Today, the company released Phase II data and news for its psoriasis drug CC-10004. The recent study showed positive results and the company announced plans to increase dosages. 
  • Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) shares continued to take a beating after they announced their earnings release date this morning. They had a rough quarter after the FDA rejected their genetic blood-thinner in November, losing about 60% of its share price. Shares are down $0.37 to $7.54 at mid-day. 
  • Omrix Biopharmaceuticals, Inc. (NASDAQ:OMRI) shares are slightly recovering today after a sharp plummet over the last 2 weeks following the FDA approval for competitor ZymoGenetics’ (ZGEN) Recothrom, that will compete with Omrix’s Evithrom in the thrombin drug market. Omrix announced last Friday that their CFO is resigning. Shares are up 4% to $21.27 on relatively heavy trading volume at mid-day. A month ago, shares were trading at over $30. 
  • Sinovac Biotech Ltd. (AMEX:SVA), the Chinese vaccine provider, has shares up over 5% to $4.11 at mid-day after Sinovec announced the private placement of 2,500,000 common shares for $9.75 million to Sansar Capital Management. 
  • StemCells Inc. (NASDAQ:STEM) stock continued to rise after news last Thursday that it plans to collaborate with Casey Eye Institute to study their leading product candidate, HuCNS-SC, a probable treatment for retinal degeneration which is a leading cause of blindness. Shares are up over 15% at mid-day to $1.77.

Rachel Lopez
February 4, 2008

Posted on: February 4, 2008 – 2:41 pm in Biotech, , , , , , , ,

The 52-Week Low Club

Orbitz Worldwide (OWW) No real news here. Maybe high oil prices could hurt travel. So far, the drop is odd. Down to $8.50 from 52-week high of $15.

US Airways (LCC) Bad traffic. High oil. Drops to $22.69 from 52-week high of $63.27.

Omnicare (OCR) Recent forecast was poor. Down to $25.31. But, no big news. The 52-week $44.87.

Momenta Pharmaceuticals (MNTA) Drug trial fails. Drops to $5.50 from 52-week high of $21.98.

Cognizant Technology (CTSH) Q4 forecast misses Wall St. estimates. Down to $31.15 from 52-week high of $47.78.

Douglas A. McIntyre

Posted on: November 6, 2007 – 4:02 pm in HI/LOW, , , , ,

Momenta Pharma (MNTA) Down 46%

Shares of Momenta Pharma (MNTA) are off 46% to $7.27, a 52-week low. The company said said Tuesday the Food and Drug Administration denied approval for its blood clot drug enoxaparin sodium, being developed with partner Novartis.

Douglas A. McIntyre

Read More »

Posted on: November 6, 2007 – 9:35 am in FDA,

Pre-Market Stock News (November 6, 2007)

  • Archer-Daniels Midland (ADM) $0.71 vs. $0.59 est.
  • Asset Acceptance Corp. (AACC) -$0.05 EPS vs -$0.05 est.
  • Beazer (BZH) cutting 1/4 workers and suspends dividend; sees new order down 50%.
  • Church & Dwight (CHD) $0.69 EPS vs. $0.589 est.; sees 2007 EPS $2.42-2.44 vs. $2.36 consensus.
  • Cooper Tire (CTB) $0.28 EPS vs $0.30 est.
  • El Paso (EP) $0.22 EPS vs $0.23 est.
  • Emerson (EMR) $0.78 EPS vs $0.75 est.
  • Environmental Tectonics’ (ETC) Aeromedical division won two new contract awards in Middle-East worth a total of $20 million.
  • Fuel-Tech (FTEK) $0.04 EPS vs. $0.06 est.; sees 2007 revenues $76-79 million vs. $79.7 million est.
  • Gerdau AmeriSteel (GNA) $0.40 EPS vs $0.42 est.
  • Google (GOOG) up $25 on analyst Sanford Bernstein raised target to $850.
  • International Securities Exchange (ISE) $0.62 EPS vs $0.53 est.
  • Kellwood (KWD) sets 2008 targets of $1.55 billion revenue from operations and sees $1.50 EPS.
  • K-Swiss (KSWS) $0.36 EPS vs $0.34 est.
  • Momenta Pharma (MNTA) announced FDA letter received says its M-Enoxaparin ANDA is NOT Approvable in current form.
  • Nortel Networks (NT) $0.05 EPS after charges vs. $0.11 est.; Revenues $2.71 Billion vs. $2.77 Billion est.
  • PetroQuest (PQ) $0.16 EPS vs. $0.14 est.
  • PowerSecure $0.15 EPS vs. $0.17 est.
  • QLogic (QLGC) announced a $200 million share buyback plan.
  • Sun Micro (JAVA) up 1.5% after earnings, despite lackluster report.
  • TheStreet.com (TSCM) $0.13 EPS vs $0.12 est.; Revenues $16.1 million vs. $16.3M est.
  • Urban Outfitters (URBN) sees revenues for Q3 at $379.3 million versus $374.5 million est.; s-s-s +8% for the quarter.
  • Valero (VLO) $1.40 EPS vs $1.35 est., but had lowered preliminary numbers.
  • Watson Pharma (WPI) $0.33 EPs vs $0.30 est.

Jon C. Ogg
November 6, 2007

Posted on: November 6, 2007 – 8:25 am in Pre-Market Activity, , , , , , , , , , , , , , , , , , , , , , ,